What is the first-line treatment regimen for Hodgkin's Lymphoma during pregnancy?

The first-line treatment regimen for Hodgkin's Lymphoma during pregnancy is Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine, commonly referred to as the ABVD regimen. This combination chemotherapy is considered effective and safer for both the mother and the developing fetus compared to other regimens.

Administering treatment during pregnancy requires careful consideration of potential teratogenic effects. ABVD has been studied and shown to have a more favorable safety profile during pregnancy than other chemotherapy regimens, such as the MOPP regimen which includes vincristine. While the use of chemotherapy in pregnancy must be cautiously monitored and ideally delayed until the second trimester to minimize risks, ABVD's components, particularly Doxorubicin and Vinblastine, have been associated with lower risks of adverse outcomes compared to alternatives.

Using chemotherapy postpartum or relying solely on radiation therapy are generally not ideal first-line approaches in the management of Hodgkin's Lymphoma because immediate treatment may be necessary to manage the progression of disease, and radiation therapy alone may not provide the comprehensive treatment required for effective disease control in a pregnant patient. These alternatives might be considered under specific circumstances but are not the standard of care for an active malignancy during pregnancy